Su Jiansheng, Liu Tingshan, Wang Min, Xu Wansong, Liu Junle, Lan Jianning, Chen Yujuan, Xu Huo, Guo Danhua, Lai Zhongmeng
Department of Anesthesiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China.
College of Materials and Chemical Engineering, Minjiang University, Fuzhou, Fujian, 350108, China.
Anal Chim Acta. 2025 Jan 15;1334:343419. doi: 10.1016/j.aca.2024.343419. Epub 2024 Nov 13.
The enzyme-free amplification technique using the Hybridization Chain Reaction (HCR) is gaining traction for its efficiency in miRNA analysis. Conventional HCR (C-HCR) with hairpin probes faces challenges due to enzymatic degradation in body fluids, leading to potential false-positive results. This study addresses the critical need for a more reliable method that resists enzymatic breakdown and improves diagnostic accuracy for detecting miRNA related to ischemic stroke. We have developed a novel DNA tetrahedral nanostructures-mediated HCR (DTN-HCR) platform for the precise detection of microRNA-25 (miR-25), a biomarker for ischemic stroke. Incorporating two unique DNA tetrahedral nanostructures with embedded hairpin structures (DTN-HP1 and DTN-HP2), this platform activates upon miR-25 binding, initiating a robust DTN-HCR reaction. This reaction forms extensive DNA tetrahedron clusters that significantly boost the fluorescence signal, enabling detection thresholds as low as 5.4 pM. The method showcases exceptional specificity by distinguishing target miRNA from close analogues and maintains structural integrity against DNase I and fetal bovine serum (FBS), verified through polyacrylamide gel electrophoresis (PAGE). It successfully differentiates ischemic stroke patients from healthy controls by analyzing peripheral blood-derived miRNAs. This study concludes that the DTN-HCR platform substantially enhances the specificity and stability of miRNA detection, marking a significant advancement in non-enzymatic miRNA analysis techniques. With its capability to accurately identify ischemic stroke biomarkers at very low concentrations and its resistance to enzymatic degradation, the DTN-HCR method presents a valuable diagnostic tool for ischemic stroke, potentially improving early detection and monitoring in a clinical environment.
利用杂交链式反应(HCR)的无酶扩增技术因其在miRNA分析中的高效性而越来越受到关注。带有发夹探针的传统HCR(C-HCR)由于在体液中会被酶降解,面临挑战,可能导致潜在的假阳性结果。本研究满足了对一种更可靠方法的迫切需求,该方法能抵抗酶解并提高检测与缺血性中风相关miRNA的诊断准确性。我们开发了一种新型的DNA四面体纳米结构介导的HCR(DTN-HCR)平台,用于精确检测缺血性中风的生物标志物——微小RNA-25(miR-25)。该平台结合了两种带有嵌入发夹结构的独特DNA四面体纳米结构(DTN-HP1和DTN-HP2),在与miR-25结合后激活,引发强烈的DTN-HCR反应。该反应形成大量的DNA四面体簇,显著增强荧光信号,检测阈值低至5.4 pM。该方法通过区分目标miRNA与相似类似物展现出卓越的特异性,并通过聚丙烯酰胺凝胶电泳(PAGE)验证,对DNase I和胎牛血清(FBS)保持结构完整性。通过分析外周血来源的miRNA,它成功地将缺血性中风患者与健康对照区分开来。本研究得出结论,DTN-HCR平台大大提高了miRNA检测的特异性和稳定性,标志着非酶miRNA分析技术取得了重大进展。凭借其在极低浓度下准确识别缺血性中风生物标志物的能力以及对酶降解的抗性,DTN-HCR方法为缺血性中风提供了一种有价值的诊断工具,有可能改善临床环境中的早期检测和监测。